PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30453718-4 2018 The expression of AKT protein was significantly inhibited in the celecoxib (CLB) group, the Feiliuping Gao (FLP) combination with cyclophosphamide (FLP+CTX) group, and the Feiliuping Gao combination with celecoxib (FLP+CLB) group (P<0.05). Celecoxib 65-74 thymoma viral proto-oncogene 1 Mus musculus 18-21 30182439-0 2019 Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. Celecoxib 0-9 thymoma viral proto-oncogene 1 Mus musculus 21-24 30182439-0 2019 Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. Celecoxib 0-9 thymoma viral proto-oncogene 1 Mus musculus 97-100 30182439-6 2019 The results revealed that if celecoxib was administered in the early stage of AKT/c-Met-induced HCC, it resulted in disease stabilization. Celecoxib 29-38 thymoma viral proto-oncogene 1 Mus musculus 78-81 30182439-9 2019 In addition, celecoxib efficiently repressed the phosphor-Akt (Thr308)/fatty acid synthase (FASN) axis both in vivo and in vitro. Celecoxib 13-22 thymoma viral proto-oncogene 1 Mus musculus 58-61 30182439-10 2019 Altogether, this study suggests that celecoxib exerts its antilipogenic efficacy by targeting a COX-2/AKT/FASN cascade, which contributes to its ability to delay hepatocarcinogenesis. Celecoxib 37-46 thymoma viral proto-oncogene 1 Mus musculus 102-105 34301977-8 2021 MDR1 down-regulation via the Akt/NF-kappaB pathway by celecoxib was confirmed, using an NF-kappaB inhibitor, CAPE. Celecoxib 54-63 thymoma viral proto-oncogene 1 Mus musculus 29-32 30453718-4 2018 The expression of AKT protein was significantly inhibited in the celecoxib (CLB) group, the Feiliuping Gao (FLP) combination with cyclophosphamide (FLP+CTX) group, and the Feiliuping Gao combination with celecoxib (FLP+CLB) group (P<0.05). Celecoxib 204-213 thymoma viral proto-oncogene 1 Mus musculus 18-21 30453718-11 2018 Feiliuping ointment combination with celecoxib has an advantage in regulating the expression of PI3K/AKT/NF-kappaB molecules in lung metastatic microenvironment. Celecoxib 37-46 thymoma viral proto-oncogene 1 Mus musculus 101-104 26512452-10 2016 Mechanistic studies revealed that celecoxib-induced cardiac protection against CH and cardiac dysfunction was due to inhibition of apoptosis via the murine double mimute 2/P53 pathway, inhibition of inflammation via the AKT/mTOR/NF-kappaB pathway and inhibition of oxidative stress via increases in nuclear factor E2-related factor-2-mediated gene expression of multiple antioxidants. Celecoxib 34-43 thymoma viral proto-oncogene 1 Mus musculus 220-223 26723251-6 2016 Celecoxib attenuated the severity of liver steatohepatitis and reduced the number of apoptotic cells, accompanied by increasing the activity of Akt and decreasing expression of p53. Celecoxib 0-9 thymoma viral proto-oncogene 1 Mus musculus 144-147 22140606-4 2011 RESULTS: Treatment with high doses of gamma-tocotrienol or celecoxib alone inhibited Akt activation and downstream signaling and NFkappaB activation. Celecoxib 59-68 thymoma viral proto-oncogene 1 Mus musculus 85-88 25665524-5 2015 Importantly, the FDA-approved drug celecoxib re-establishes the AKT/miR-199a-5p/CAV1 axis in CF macrophages, and ameliorates lung hyper-inflammation in Cftr-deficient mice. Celecoxib 35-44 thymoma viral proto-oncogene 1 Mus musculus 64-67 21430081-0 2011 Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. Celecoxib 0-9 thymoma viral proto-oncogene 1 Mus musculus 75-78 21430081-1 2011 Celecoxib, a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug, has been shown to inhibit Akt and prevent cardiac remodeling in aortic banding-induced failing heart in mice. Celecoxib 0-9 thymoma viral proto-oncogene 1 Mus musculus 111-114 21430081-3 2011 Since 2,5-dimethyl (DM)-celecoxib, a derivative unable to inhibit COX-2, has been also reported to inhibit Akt, we attempted to examine whether DM-celecoxib retains the ability to prevent cardiac remodeling and improve cardiac functions using a mouse model of inherited dilated cardiomyopathy (DCM). Celecoxib 24-33 thymoma viral proto-oncogene 1 Mus musculus 107-110 21430081-8 2011 These results suggested that not only celecoxib but also DM-celecoxib prevents cardiac remodeling and reduces mortality in DCM through a COX-2-independent mechanism involving Akt and its downstream mediators. Celecoxib 38-47 thymoma viral proto-oncogene 1 Mus musculus 175-178 24647425-0 2014 Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model. Celecoxib 49-58 thymoma viral proto-oncogene 1 Mus musculus 138-141 24647425-10 2014 The expression of PI3K, P-Akt, COX-2, HIF-1alpha, VEGF-A and PTEN in tumor tissues treated with celecoxib was demonstrated by immunohistochemistry, and the MVD was decreased in a dose-dependent manner (P<0.05). Celecoxib 96-105 thymoma viral proto-oncogene 1 Mus musculus 26-29 24647425-11 2014 Reduced PI3K and P-Akt was particularly apparent in the high-dose celecoxib group (P<0.05). Celecoxib 66-75 thymoma viral proto-oncogene 1 Mus musculus 19-22 24647425-12 2014 ELISA and western blotting data showed that the expression of PI3K, P-Akt, COX-2, HIF-1alpha and VEGF-A were reduced and PTEN was increased after treatment with celecoxib. Celecoxib 161-170 thymoma viral proto-oncogene 1 Mus musculus 70-73 24647425-13 2014 In conclusion, the impact of celecoxib-induced tumor growth delay of murine H22 hepatocarcinoma may correlate with the inhibition of angiogenesis by reducing PI3K, P-Akt, COX-2, HIF-1alpha and VEGF-A expression and increasing PTEN expression in tumor tissue. Celecoxib 29-38 thymoma viral proto-oncogene 1 Mus musculus 166-169 22140606-8 2011 CONCLUSION: The synergistic anticancer effects of combined low dose gamma-tocotrienol and celecoxib treatment in +SA mammary tumor cells are mediated by COX-2-dependent mechanisms associated with a suppression in PGE(2) levels, as well as, COX-2-independent mechanisms associated with a reduction in ErbB2-4 receptor levels, activation, and subsequent reduction in downstream Akt and NFkappaB mitogenic signaling. Celecoxib 90-99 thymoma viral proto-oncogene 1 Mus musculus 376-379 17285134-8 2007 Celecoxib increased apoptosis in MCF7/HER2-18 tumours (TUNEL 0.52% control vs 0.73% treated, P=0.0004) via inactivation of AKT (median pAKT(ser473) 57.3% control vs 35.5% treated, P=0.0001--confirmed at Western blotting). Celecoxib 0-9 thymoma viral proto-oncogene 1 Mus musculus 123-126 15570007-11 2004 Down-regulation of AKT protein (total and phosphorylated at Ser473) signaling by celecoxib clearly indicates an inhibition of the survival gene and the pathological process that could otherwise lead to adenocarcinoma. Celecoxib 81-90 thymoma viral proto-oncogene 1 Mus musculus 19-22 21205474-12 2010 Western blot analysis demonstrated that the combination of celecoxib and fluvastatin significantly down-regulated p-Akt (0.23+/-0.08 versus 1.12+/-0.07 and surviving (0.50+/-0.07 versus 1.47+/-0.19) in BEL-7402 tumours compared with the control (P value is less than 0.01 for all). Celecoxib 59-68 thymoma viral proto-oncogene 1 Mus musculus 116-119